The objective of the paper is to review the literature and provide recommendations for use of aminoglycoside antibiotics in critically ill obese patients. Literature search in PubMed for all articles on the use of aminoglycosides in critically ill obese patients was conducted, and all articles related to pharmacokinetics in obesity were reviewed. Bibliographies of all searched manuscripts were ...

Aminoglycoside represents a class of versatile and broad spectrum antibacterial agents. In an effort to revive the antibacterial activity against aminoglycoside resistant bacteria, our laboratory has developed two new classes of aminoglycoside, pyranmycin and amphiphilic neomycin (NEOF004). The former resembles the traditional aminoglycoside, neomycin. The latter, albeit derived from neomycin, ...

The action of aminoglycoside antibiotics is inhibited by chemical modification catalyzed by aminoglycoside inactivating enzymes, which bind these cationic saccharides with active site pockets that contain a preponderance of negatively charged residues. In this study, it was observed that several cationic antimicrobial peptides, representing different structural classes, could serve as inhibitor...

The majority of riboswitches are regulatory RNAs that regulate gene expression by binding small-molecule metabolites. Here we report the discovery of an aminoglycoside-binding riboswitch that is widely distributed among antibiotic-resistant bacterial pathogens. This riboswitch is present in the leader RNA of the resistance genes that encode the aminoglycoside acetyl transferase (AAC) and aminog...

The antibacterial activity of netilmicin (Sch 20569), a new semisynthetic aminoglycoside, was compared with that of gentamicin against a variety of gram-negative bacteria, staphylococci, and streptococci. Both antibiotics had similar activity against most organisms, but netilmicin had appreciably greater activity against gram-negative organisms that were resistant to gentamicin because these sp...

Aminoglycoside-modifying enzymes among Proteus mirabilis aminoglycoside-modifying enzymes, Proteus mirabilis, ESBL, plasmid-mediated resistance

Educational Objectives 1. Describe and calculate the dosage regimen of an aminoglycoside antibiotic for a patient with Gram negative sepsis. 2. Define the half-live of an aminoglycoside when given serum concentration time data. 3. Calculate the distribution volume of an aminoglycoside in a patient when given serum concentration time data. 4. Describe the physiologic variables which will change ...

Bacillus circulans NRRL B-3312 produces the aminoglycoside antibiotic butirosin and encodes an aminoglycoside 3'-phosphotransferase. We detected a 48 kilobase plasmid, pIP850, in this strain; this was analyzed by agarose gel electrophoresis following digestion with EcoRI restriction endonuclease and by nucleic acid hybridization. The results obtained indicate that plasmid pIP850 does not carry ...

A 5-year nationwide prospective study in Sweden during 1995-1999 identified 881 definite episodes of infective endocarditis. Definite enterococcal endocarditis was diagnosed in 93 episodes (11%), the largest series of enterococcal endocarditis so far presented. Mortality during treatment was 16%, the relapse rate was 3%, and clinical cure was achieved in the remaining 81% of the episodes. Clini...